All news

29 October 2026

Merck beats forecasts as its under-the-skin Keytruda shot takes off

Merck's third-quarter sales rose 5% to $18.09 billion, with its cancer drug Keytruda bringing in $8.6 billion, and the company raised its full-year adjusted profit outlook.

Merck's biggest drug is getting a second act before its first one ends. On Thursday the drugmaker beat Wall Street's third-quarter forecasts, helped by its cancer medicine Keytruda and especially by a newer version of it that patients get as a quick injection under the skin.

What happened

Revenue rose 5% from a year earlier to $18.09 billion, above the $17.31 billion analysts expected in an LSEG survey. Adjusted earnings, which leave out acquisition and restructuring costs, were $2.49 a share versus $2.08 expected. On the standard accounting measure, net income fell to $5.07 billion from $5.79 billion a year earlier.

Keytruda alone brought in $8.60 billion, nearly half of all Merck's sales and well above the $7.73 billion analysts expected, according to StreetAccount. That total includes $830 million from Keytruda Qlex, the injectable form launched in 2025, which had its best quarter yet and beat a $649 million estimate.

  • Gardasil, the HPV vaccine, sold about $2 billion on stronger US demand, after a weak patch last year tied to excess stock and soft demand in China.
  • Winrevair, for a rare and deadly lung condition, grew 93% to $694 million.
  • The animal health business came in a little below estimates at $1.68 billion.

Merck raised its adjusted profit outlook to $2.77 to $2.82 a share, from $2.66 to $2.76, a figure that now includes a $400 million charge for a licensing deal with Chinese cancer drugmaker SciBrunch. It also lifted the bottom of its 2026 revenue range, which is now $66.8 billion to $67.3 billion.

Why it matters

Key Keytruda patents start to expire in 2028. A patent gives a company the sole right to sell a drug for a set time; once it lapses, rivals can sell cheaper copies, and sales of the original usually drop fast. For a drug that makes up close to half of Merck's revenue, that is the single biggest risk to the business.

Qlex is a large part of Merck's answer. The plan is to move patients from the original version, given through a drip into a vein, to the more convenient shot, which is protected for longer. Merck has also been striking deals to add new drugs before 2028 arrives. The company was worth about $350 billion at Tuesday's close, according to Noorult data.

What to watch

  • How quickly Qlex sales keep climbing, the clearest sign of whether patients are switching over.
  • More deals as Merck tries to fill the gap Keytruda copies will leave.
  • Whether Gardasil's recovery holds now that US demand has picked up.

Merck's full financials are on its Noorult company page.

The companies in this story

Based on reporting by CNBC: Merck (MRK) earnings Q3 2026. Facts, not advice.

More news